Delete lines 6 through 12 of the printed bill and insert:

"SECTION 1. (1) The Department of Consumer and Business Services, as part of the prescription drug transparency program described in ORS 646A.689, shall conduct a study of disparities in the cost of hormone replacement drugs between those for men and those for women.

(2) The department shall report the findings of its study to the Legislative Assembly, in the manner provided in ORS 192.245, no later than September 15, 2022. The report shall include recommendations for legislative changes, if necessary, to address disparities in the costs of hormone replacement drugs based on sex.".